Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05295693
Other study ID # Quantra vs TEG
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 13, 2022
Est. completion date May 25, 2023

Study information

Verified date March 2024
Source Stanford University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Congenital heart surgery on cardio-pulmonary bypass (CPB) is associated with impacted coagulation quality and increased bleeding after separation of CPB. The current testing device used at our institution is the "TEG 5000" (Haemonetics Corporation). The novel coagulation testing device "Quantra System" (Hemosonics) has favorable properties (result within 20 minutes) allowing for a quicker identification of the coagulation problem and hence faster administration of the correct coagulation products, potentially leading to better coagulation quality and possibly reducing the need of additional blood products. The aim of this prospective observational (non-interventional, investigational only) quality improvement study is to investigate if the Quantra is reliable and valid in predicting the coagulation status when compared with our standard-of-care device TEG 5000.


Description:

Congenital heart surgery on cardio-pulmonary bypass (CPB) is associated with impacted coagulation quality and increased bleeding after separation of CPB. Therefore, coagulation products and blood products often need to be given/transfused during these cases. The correct choice and dosing of coagulation products is essential to effectively stop bleeding and reduce the need of additional blood transfusion. The current testing device used at our institution during congenital heart surgery on CPB is the TEG 5000 (Haemonetics Corporation). Prior to separation from CPB (mostly 30-60 minutes) and after the first coagulation products were given (approx. 60 minutes after separation from CPB) a Clauss Fibrinogen and a TEG are drawn. These samples are sent to an off-site lab for processing and time to result ranges from 60-90 minutes. Therefore, results are often not present when needed. An easy to use point-of-care (POC) test device being readily available in the operation room and allowing for rapid results could result in quicker identification of the coagulation problem and hence allow for faster administration of the correct coagulation products, potentially leading to better coagulation quality and possibly reducing the need of additional blood products. The Quantra System (Hemosonics) is an easy-to-use, stand-alone device presenting results within 20 minutes. With these properties all above mentioned problems would be addressed. To date the Quantra has not been used and has not been evaluated in patients with congenital heart disease for cardiac surgery on CPB. The aim of this prospective observational (non-interventional, investigational only) quality improvement study is to investigate if the Quantra is reliable and valid in predicting the coagulation status when compared with our standard-of-care device TEG All patients who are enrolled in this study will be patients who are scheduled to undergo cardiac surgery and who require a general anesthesia, endotracheal intubation, arterial line placement and coagulation testing as part of standard of care for the surgery. No patient will have a general anesthesia, endotracheal intubation, arterial line inserted or coagulation testing for research purposes only. If the family/patient consent to be enrolled in the study the patient will be included in the study. It is standard of care to draw blood samples for coagulation testing (TEG and Clauss Fibrinogen) prior to separation of cardio-pulmonary-bypass (t1) and after the first coagulation products were given (t2), resulting in 2 x 5.4mL of blood. For testing of efficacy/reliability/validity of the Quantra System we will need to draw additional blood samples (2.7mL) for each time point t1 and t2, resulting in a total of 2 x 2.7mL. These extra 5.4mL of blood drawn during the research portion of this study is additional to what they need for the surgical procedure and is not standard of care. No clinical decision will be made on the results of the Quantra System. This is an investigational, non-interventional study.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date May 25, 2023
Est. primary completion date May 25, 2023
Accepts healthy volunteers No
Gender All
Age group N/A to 8 Years
Eligibility Inclusion Criteria: - All cases with hypothermia (<=30C) Exclusion Criteria: - Neonatal/Infant Bloodless surgery - Bodyweight under 3kg

Study Design


Intervention

Device:
Correlation of the Quantra with the TEG
The purpose of this study is to evaluate the efficacy/reliability/validity of the Quantra device in patients with congenital heart disease for cardiac surgery on CPB. The study if of investigational interest only. No clinical decisions will be made based on the results obtained by the Quantra device.

Locations

Country Name City State
United States Stanford University Palo Alto California

Sponsors (1)

Lead Sponsor Collaborator
Stanford University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Correlation Quantra vs TEG_Fibrinogen_Function1 Correlation/Linear regression/normal_vs_abnormal of Quantra (FCS) with TEG (K time & alpha angle) 30 minutes during anesthesia, prior to separation from CPB
Primary Correlation Quantra vs TEG_Fibrinogen_Function1 Correlation/Linear regression/normal_vs_abnormal of Quantra (FCS) with TEG (K time & alpha angle) 30 minutes during anesthesia, after coagulation products were given
Primary Correlation Quantra vs TEG_Fibrinogen_Function2 Correlation/Linear regression/normal_vs_abnormal of Quantra (FCS) with Clauss Fibrinogen. 30 minutes during anesthesia, prior to separation from CPB
Primary Correlation Quantra vs TEG_Fibrinogen_Function2 Correlation/Linear regression/normal_vs_abnormal of Quantra (FCS) with Clauss Fibrinogen. 30 minutes during anesthesia, after coagulation products were given
Primary Correlation Quantra vs TEG_Platelet_Function Correlation/Linear regression/normal_vs_abnormal of Quantra (CS/PCS) with TEG (MA) 30 minutes during anesthesia, prior to separation from CPB
Primary Correlation Quantra vs TEG_Platelet_Function Correlation/Linear regression/normal_vs_abnormal of Quantra (CS/PCS) with TEG (MA) 30 minutes during anesthesia, after coagulation products were given
Primary Correlation Quantra vs TEG_clot initiation Correlation/Linear regression/normal_vs_abnormal of Quantra (CT/CTH) with TEG (R time) 30 minutes during anesthesia, prior to separation from CPB
Primary Correlation Quantra vs TEG_clot initiation Correlation/Linear regression/normal_vs_abnormal of Quantra (CT/CTH) with TEG (R time) 30 minutes during anesthesia, after coagulation products were given
Primary Correlation Quantra vs TEG_clot strength/firmness Correlation/Linear regression/normal_vs_abnormal of Quantra (CS) with TEG (G value) 30 minutes during anesthesia, prior to separation from CPB
Primary Correlation Quantra vs TEG_clot strength/firmness Correlation/Linear regression/normal_vs_abnormal of Quantra (CS) with TEG (G value) 30 minutes during anesthesia, after coagulation products were given
See also
  Status Clinical Trial Phase
Recruiting NCT01912547 - Thromboelastography During Surgery for Malignant Pleural Mesothelioma Phase 0
Completed NCT03674684 - ROTEM Assessment of Modern Crystalloid, Hydroxyethyl Starch and Gelatin Effect on Coagulation
Recruiting NCT05874843 - Validation of Point-of-care Thromboelastography (TEG 6s) in Pediatric Patients N/A
Withdrawn NCT04705701 - Comparing Post Cardiac Surgery Outcomes in ESRD Patient's With Early Dialysis Versus Standard Care N/A
Not yet recruiting NCT04515420 - The Influence of Noradrenaline on Coagulation and Fibrinolysis in Severe Isolated Brain Injury
Completed NCT01598831 - Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy Phase 3
Completed NCT04580563 - Study Assessing Efficacy of Plasmatherapy in Septic Shock-induced Coagulopathy: Feasibility Study N/A
Withdrawn NCT04274699 - Clinical Evaluation of the Hemosonics Quantra® Coagulation Monitor in Liver and Multivisceral Transplantation
Terminated NCT02540434 - Trial of RiaSTAP Versus Cryoprecipitate to Lower Operative Transfusions N/A
Completed NCT02203968 - Fibrinogen in the Initial Resuscitation of Severe Trauma (FiiRST) Phase 1/Phase 2
Unknown status NCT01854476 - Safety and Efficacy Study Comparing Pad-gauze With Anti-fibrinolytic Agent Hemostopan™) to a Regular Pad-gauze Phase 2/Phase 3
Completed NCT00816127 - Prevention of Bleeding in Patient With Cirrhosis Undergoing Dental Extraction N/A
Active, not recruiting NCT02926274 - Transfusion Using Stored Whole Blood N/A
Not yet recruiting NCT04582188 - The Early Coagulopathy for the Prognosis in Sepsis
Recruiting NCT04528888 - Steroids and Unfractionated Heparin in Critically Ill Patients With Pneumonia From COVID-19 Infection Phase 3
Recruiting NCT05449834 - Fibrinogen Early In Severe Trauma StudY II Phase 3
Withdrawn NCT04435015 - The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular Complications Phase 1/Phase 2
Not yet recruiting NCT04115722 - Coagulation Parameters in IBD Patients
Completed NCT01228058 - A Prospective Evaluation of Thromboelastography for Identifying Coagulopathy in Severely Injured Patients N/A
Active, not recruiting NCT04128488 - Effects of Gender-Affirming Hormone Therapy Among Transgender Women